Bristol Myers Squibb’s (BMY) Buy Rating Reaffirmed at Guggenheim

Guggenheim reissued their buy rating on shares of Bristol Myers Squibb (NYSE:BMY) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $72.00 price objective on the biopharmaceutical company’s stock.

BMY has been the topic of several other research reports. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. UBS Group restated a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Wells Fargo & Company restated an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Barclays assumed coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $61.35.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $59.20 on Wednesday. The stock has a fifty day simple moving average of $59.60 and a two-hundred day simple moving average of $52.98. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89. The firm has a market cap of $120.86 billion, a price-to-earnings ratio of 17.16, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the company posted $1.67 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.09% of the company’s stock.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northwestern Mutual Investment Management Company LLC raised its position in shares of Bristol Myers Squibb by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after buying an additional 172 shares in the last quarter. KCM Investment Advisors LLC raised its position in shares of Bristol Myers Squibb by 0.8% in the fourth quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after buying an additional 174 shares in the last quarter. Investment Research Partners LLC raised its position in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after buying an additional 179 shares in the last quarter. ESG Planning DBA Harper Investing raised its position in shares of Bristol Myers Squibb by 1.3% in the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after buying an additional 180 shares in the last quarter. Finally, REAP Financial Group LLC raised its position in shares of Bristol Myers Squibb by 26.1% in the fourth quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 182 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.